What Biogen’s Alzheimer’s Drug Results Means for the Company’s Stock
Yesterday, we discussed how Crispr stock enjoyed a short-lived jump ahead of seeking FDA approval for their gene therapy drug. But today, we’re here to talk about a drug company that has experienced a much larger spike as a result of positive news: Biogen. Biogen is engaged in discovering, developing, and delivering therapies for [...]